Skip to main content
Eurobio Scientific logo

Eurobio Scientific — Investor Relations & Filings

Ticker · ALERS ISIN · FR0013240934 LEI · 969500IQEUEH806GE257 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2023-05-23 Regulatory Filings
Country FR France
Listing PA ALERS

About Eurobio Scientific

https://www.eurobio-scientific.com

Eurobio Scientific is an integrated company specializing in in vitro diagnostics (IVD). Its activities cover the entire value chain, from research and development to the manufacturing and commercialization of specialty diagnostic products. The company's core focus areas are transplantation, oncology, and infectious diseases. In transplantation, it provides reagents, software for transplant matching and chimerism monitoring, and culture media for cornea grafts. For oncology, it develops and manufactures prognostic genomic tests for breast and prostate cancer. The group also markets a comprehensive portfolio of molecular tests for detecting infectious diseases, alongside solutions for immunology, fertility, and dermatological conditions.

Recent filings

Filing Released Lang Actions
Eurobio Scientific becomes one of the first European companies to obtain IVDR1 CE marking of PCR tests
Regulatory Filings Classification · 95% confidence The document is a press release dated May 23, 2023, announcing that Eurobio Scientific obtained IVDR CE marking for its PCR tests. It details regulatory achievements (IVDR CE marking, ISO 13485:2016 certification renewal) and discusses regulatory expertise. This type of announcement, focusing on a specific operational or regulatory milestone rather than periodic financial results (like ER or IR) or management changes (MANG), fits best under a general regulatory announcement or news release category. Since it is not a formal financial report (10-K, IR, ER) or a specific corporate action announcement (CAP, DIV, SHA), and it is a formal announcement of a significant regulatory achievement, it is classified as a Regulatory Filing (RNS) as the most appropriate general category for non-standard, material corporate news that doesn't fit the other specific codes. The document length is substantial (6486 chars), so it is not an RPA.
2023-05-23 English
Eurobio Scientific : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2022
Report Publication Announcement Classification · 98% confidence The document is titled "MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2022" (Making available of the 2022 Annual Financial Report). It explicitly states that Eurobio Scientific has made available and filed its annual financial report for the year ended December 31, 2022, with the AMF (Autorité des Marchés Financiers) on April 28, 2023. The document itself is very short (2668 characters) and serves primarily to announce that the full report is available elsewhere (on the company website). According to Rule #2 (The "MENU VS MEAL" Rule), a short announcement stating that a report has been published or made available points towards a Report Publication Announcement (RPA) rather than the full report itself (which would typically be a 10-K or IR, but this is an announcement *of* the report).
2023-04-28 French
Eurobio Scientific: RESULTATS ANNUELS 2022 - Très solide performance et renforcement du Cœur d’Activité
Earnings Release Classification · 100% confidence The document is titled "RESULTATS ANNUELS 2022" (Annual Results 2022) and presents a detailed summary of the company's consolidated financial performance for the full year 2022, including key metrics like revenue, EBITDA, net income, and balance sheet items. It explicitly states that the annual consolidated results were presented on April 5, 2023. This content aligns perfectly with the definition of an Annual Report, which covers full company activity and financial performance for the year. Although the text mentions that the audit procedures are still ongoing (footnote 2), the document itself is structured as the primary annual financial disclosure, making '10-K' (Annual Report) the most appropriate classification, even if it is a French equivalent disclosure rather than the specific SEC Form 10-K. FY 2022
2023-04-05 French
Eurobio Scientific : 2022 ANNUAL RESULTS - Very strong performance and strengthening of the Core Business
Earnings Release Classification · 100% confidence The document is explicitly titled "2022 ANNUAL RESULTS" and contains detailed consolidated financial tables for the year 2022 compared to 2021, including Revenues, EBITDA, Net Result, and cash flow analysis. This content is characteristic of a full annual financial report. Although it mentions the audit procedures are still being carried out (footnote 2), the document itself presents the comprehensive annual financial performance summary. This aligns best with the definition of an Annual Report (10-K), which covers full yearly performance. It is not merely an Earnings Release (ER) as it is comprehensive, nor is it an Interim Report (IR) as it covers the full year. The mention of the Annual Shareholders' Meeting date is secondary to the primary financial content. FY 2022
2023-04-05 English
Eurobio Scientific : Wietse Mulder, CEO de GenDx, détient 2% du capital
Major Shareholding Notification Classification · 98% confidence The document is a press release dated February 14, 2023, announcing that Wietse Mulder, CEO of the recently acquired GenDx, has crossed the 2% shareholding threshold in Eurobio Scientific via his holding company, EchiumBio Holding BV. This constitutes a notification of a change in significant share ownership, as it explicitly mentions crossing a statutory threshold (2%). This aligns directly with the definition of Major Shareholding Notification (MRQ). The document also mentions a future AGM, but the primary subject is the shareholding change.
2023-02-14 French
Eurobio Scientific: Wietse Mulder, CEO of GenDx, holds a 2% stake
Director's Dealing Classification · 95% confidence The document announces that the CEO of GenDx, Wietse Mulder, acquired a 2% stake in Eurobio Scientific equity, crossing a statutory threshold. This constitutes a notification of a change in significant share ownership by an individual/entity. The document also mentions that the Board will recommend appointing Wietse Mulder as a director at the next Annual Shareholders' General Meeting, which is related to governance/shareholder matters, but the primary focus and trigger for the announcement is the shareholding crossing the 2% threshold. This aligns best with the Major Shareholding Notification (MRQ) definition, which covers changes in significant share ownership levels crossing thresholds. It is not a full Annual Report (10-K), an Earnings Release (ER), or a Director's Dealing report (DIRS, which focuses on transactions by directors of the reporting company, whereas this is an external party acquiring a stake).
2023-02-14 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.